SANGUINE CORP. (SGNC) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SANGUINE CORP. (SGNC)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Mike Ankley who wrote (3360)	7/18/1998 5:03:00 AM
From: Mike Ankley	Read Replies (1) of 5402

Green Cross assigned U.S. patent 3,962,439 Oxygen-transferable emulsion patents.uspto.gov Green Cross is the parent company of Alpha Therapeutics. Dr. Drees was President/CEO of Alpha Therapeutics for several years, during which time FDA approval to Alpha for U.S. patent 4,252,827 was achieved. ------------------------------------------------------------------------ Abstract ------------------------------------------------------------------------ Oxygen-transferable perfluorocarbon compounds having 9 to 11 carbon atoms such as perfluorodecalin, perfluoro(C(3-5) -alkylcyclohexanes), perfluoro(C(4-6) -alkyl tetrahydropyrans), perfluoro(C(5-7) -alkyltetrahydrofurans), perfluoro(C(5-7) -alkylmorpholins) and perfluoro(C(9-11) -trialkylamines) are emulsified in a physiologically acceptable aqueons solution such as Ringer's solution by the aid of a phospholipid as emulsifier and a fatty acid of 8 to 22 carbon atoms, alkali metal salt or monoglyceride thereof as emulsifying adjuvant. The emulsion is stable for a considerable period of time and contains particles having a particle size ranging from 0.05 to 0.3 mu. It is usable as a blood substitute or a perfusate for preservation of the internal organs. Cheers Mike

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next